Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Crossover, Randomized, Placebo-Controlled, Single-Blind, Repeat Dose Study in Post-Bariatric Hypoglycemia Subjects to Determine the Effect of Mizagliflozin on Adverse Events and Postprandial Glucose Excursions

NCT05721729 is registered in ClinicalTrials.gov with Vogenx, Inc. as lead sponsor.

NCT NCT05721729
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05721729 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Crossover, Randomized, Placebo-Controlled, Single-Blind, Repeat Dose Study in Post-Bariatric Hypoglycemia Subjects to Determine the Effect of Mizagliflozin on Adverse Events and Postprandial Glucose Excursions
Lead sponsor
Vogenx, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 23, 2023
Completion date
June 1, 2025
Enrollment
15 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

postbariatric hypoglycemia